How many drugs treat Prevention of migraine attacks?

Drug Landscape tracks 6 marketed treatments for Prevention of migraine attacks (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/prevention-of-migraine-attacks.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Prevention of migraine attacks — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevention of migraine attacks (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Prevention of migraine attacks, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Nurtec Odt	Rimegepant Sulfate	Pfizer	CGRP receptor antagonist	Calcitonin gene-related peptide (CGRP) receptor	2020-01-01
Vyepti	EPTINEZUMAB	Lundbeck Seattle BioPharmaceuticals, Inc.	Calcitonin Gene-related Peptide Antagonist [EPC]	Calcitonin gene-related peptide 1	2020-01-01
Nurtec Odt	rimegepant	Pfizer	Calcitonin Gene-related Peptide Receptor Antagonist	calcitonin gene-related peptide receptor	2020-01-01
Ajovy	FREMANEZUMAB	Teva		Calcitonin gene-related peptide 1	2018-01-01
Aimovig	ERENUMAB	Amgen		Calcitonin-gene-related peptide receptor	2018-01-01
VYEPTI	EPTINEZUMAB-JJMR	Lundbeck Seattle BioPharmaceuticals, Inc.	Calcitonin Gene-related Peptide Antagonist [EPC]	Calcitonin gene-related peptide 1, Calcitonin gene-related peptide 2

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Lundbeck Seattle BioPharmaceuticals, Inc. · 2 drugs in Prevention of migraine attacks
Pfizer · 2 drugs in Prevention of migraine attacks
Amgen · 1 drug in Prevention of migraine attacks
Teva · 1 drug in Prevention of migraine attacks

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Prevention of migraine attacks:

Cite this brief

Drug Landscape (2026). Prevention of migraine attacks — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-migraine-attacks. Accessed 2026-06-10.

Prevention of migraine attacks full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing